Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theravance Biopharma, Inc.TBPH · Entity 5037 | SVP, RESEARCH & DEVELOPMENT | February 20, 2024 | February 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theravance Biopharma, Inc.
Report date February 20, 2024 · Filed February 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 314,915 |
Reported balance
After 2024-02-20 transaction · row 1
1 source rowRow 1 · 2024-02-20 · Tax withholding · Disposed 19,294 · Balance 314,915 F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2024 Filed Feb 23, 2024 01:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 19,294 | $8.92 | $172,102.48 |
DisclosureSEC source: 0001415889-24-004960 · form4-02232024_010210.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,915 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 23:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 12,630 | $10.37 | $130,973.10 |
DisclosureSEC source: 0001415889-23-015448 · form4-11222023_111154.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,209 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 23:16 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,482 | $10.22 | $25,366.04 |
DisclosureSEC source: 0001415889-23-015228 · form4-11162023_111124.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 346,839 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 22:35 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-014680 · form4-11012023_101136.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,321 F1 · shares: On March 1, 2023 the reporting person was granted a performance restricted stock unit award that vests based on the achievement of a performance condition by December 31, 2023 and continued employment. On October 30, 2023 the performance conditions were achieved. As a result 50% of the restricted stock units will vest on November 20, 2023 and the remaining 50% of the restricted stock units will vest on November 20, 2024, subject to the reporting person's continued service. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 22:54 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,482 | $9.03 | $22,412.46 |
DisclosureSEC source: 0001415889-23-014412 · form4-10182023_101010.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,321 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 22:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,482 | $9.89 | $24,546.98 |
DisclosureSEC source: 0001415889-23-013342 · form4-09182023_100948.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,803 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. Read SEC document |
| August 20, 2023 Filed Aug 22, 2023 22:13 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 10,461 | $9.70 | $101,471.70 |
DisclosureSEC source: 0001415889-23-012514 · form4-08222023_100854.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,285 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 22:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,322 | $9.99 | $23,196.78 |
DisclosureSEC source: 0001415889-23-012271 · form4-08152023_100836.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 349,746 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 22:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,322 | $9.84 | $22,848.48 |
DisclosureSEC source: 0001415889-23-011244 · form4-07182023_100756.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,068 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,322 | $10.69 | $24,822.18 |
DisclosureSEC source: 0001415889-23-009963 · form4-06162023_100650.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,390 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. Read SEC document |
| May 20, 2023 Filed May 23, 2023 23:41 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 10,460 | $11.21 | $117,256.60 |
DisclosureSEC source: 0001415889-23-008670 · form4-05232023_110546.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,712 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 15, 2023 Filed May 17, 2023 22:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,322 | $11.26 | $26,145.72 |
DisclosureSEC source: 0001415889-23-008228 · form4-05172023_100533.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,172 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:49 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,323 | $11.88 | $27,597.24 |
DisclosureSEC source: 0001415889-23-006620 · form4-04182023_090429.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369,494 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 23:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,323 | $10.32 | $23,973.36 |
DisclosureSEC source: 0001415889-23-005044 · form4-03162023_110312.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,817 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 00:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,323 | $10.05 | $23,346.15 |
DisclosureSEC source: 0001415889-23-004552 · form4-03092023_120346.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,140 F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 11/23/22. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004271 · form4-03042023_010324.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,463 Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 00:21 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 12,057 | $10.44 | $125,875.08 |
DisclosureSEC source: 0001415889-23-003065 · form4-02232023_120239.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,463 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:59 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 2,084 | $10.73 | $22,361.32 |
DisclosureSEC source: 0001415889-22-012077 · form4-12052022_101216.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,520 Read SEC document |
| November 20, 2022 Filed Nov 22, 2022 21:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 27,350 | $10.85 | $296,747.50 |
DisclosureSEC source: 0001415889-22-011669 · form4-11222022_091137.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,604 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 00:53 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,800 | $11.20 | $31,360.00 |
DisclosureSEC source: 0001415889-22-011523 · form4-11182022_121128.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,954 Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 22:57 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 18,991 | $9.34 | $177,375.94 |
DisclosureSEC source: 0001415889-22-008981 · form4-08232022_030844.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,754 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 4,906 | $9.71 | $47,639.71 |
DisclosureSEC source: 0001415889-22-008835 · form4-08182022_030816.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,745 F1 · price: This transaction was executed in multiple trades at prices from $9.71 to $9.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 22:55 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 15,086 | $8.79 | $132,605.94 |
DisclosureSEC source: 0001415889-22-008512 · form4-08112022_030815.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,651 Read SEC document |
| May 20, 2022 Filed May 24, 2022 23:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,947 | $8.74 | $34,496.78 |
DisclosureSEC source: 0001415889-22-005629 · form4-05242022_040517.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,737 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 23:25 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 20,377 | $9.61 | $195,822.97 |
DisclosureSEC source: 0001415889-22-001697 · form4-02232022_030221.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,684 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| December 02, 2021 Filed Dec 7, 2021 00:51 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-010636 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,061 Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:23 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,263 | $8.36 | $35,638.68 |
DisclosureSEC source: 0001415889-21-005468 · form4-11232021_051117.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. F2 · valueOwnedAfter: Includes 119 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2021. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 22:52 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,819 | $14.05 | $95,806.95 |
DisclosureSEC source: 0001179110-21-008392 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,205 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2021 Filed May 24, 2021 22:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,410 | $17.80 | $60,698.00 |
DisclosureSEC source: 0001179110-21-005840 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,024 F1 · balance_after: Includes 1,282 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 14, 2021. Read SEC document |
| February 20, 2021 Filed Feb 23, 2021 23:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,597 | $18.79 | $123,957.63 |
DisclosureSEC source: 0001179110-21-002154 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,152 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:30 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001543 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,749 Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 23:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 7,500 | $19.47 | $146,058.00 |
DisclosureSEC source: 0001179110-20-012003 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,749 F1 · price: This transaction was executed in multiple trades at prices from $19.46 to $19.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,876 | $17.21 | $66,705.96 |
DisclosureSEC source: 0001179110-20-011365 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,249 Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009566 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,125 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,598 | $18.22 | $120,215.56 |
DisclosureSEC source: 0001179110-20-009261 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,625 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.